TCL Archive In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List December 2, 1983
TCL Archive Genentech: ODAC Lacks Expertise, Impartiality; FDA: Company’s Proposal Unscientific August 12, 2011